Cells expressing transmembrane TNFα bound to infliximab may also be susceptible to complement-mediated lysis, potentially increasing its anti-inflammatory effect.3 The dosage of infliximab varies from 3 mg/kg intravenously for rheumatoid arthritis to 5 mg/kg intravenously for Crohn disease,3,17 and it is administered at weeks 0, 2, and 6, and then every 8 weeks for up to 18 months. This evidence concerns the gene TNF and rheumatoid arthritis.